Virtual dual inhibition of COX-2/5-LOX enzymes based on binding properties of Alpha-amyrins, the anti-inflammatory compound as a promising anti-cancer drug

EXCLI Journal

Volumn 15, Issue , 2016, Pages 238-245

  Ranjbar, Mohammad Mehdi ^a   Assadolahi, Vahideh ^b   Yazdani, Mohsen ^c   Nikaein, Donya ^d   Rashidieh, Behnam ^d  

^a Department of Venomous Animals and Antivenom Production   (Iran)

^b KURDISTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Biotechnology Research Center   (Iran)

^d AVICENNA RESEARCH INSTITUTE   (Iran)

Author keywords

5 Lipooxygenase (5 LOX); Anti cancer drug; Cyclooxygenase 2 (COX2); Drug discovery; amyrins

Indexed keywords

ALPHA AMYRIN; ARACHIDONATE 5 LIPOXYGENASE; CYCLOOXYGENASE 2;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; COVALENT BOND; DRUG ABSORPTION; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; ENZYME ACTIVE SITE; ENZYME INHIBITION; HYDROGEN BOND; HYDROPHOBICITY;

EID: 84961615095     PISSN: None     EISSN: 16112156     Source Type: Journal    
DOI: 10.17179/excli2016-164     Document Type: Article

References (25)

1. Al-Awadi FM, Srikumar TS, Anim JT, Khan I. Antiinflammatory effects of Cordia myxa fruit on experimentally induced colitis in rats. Nutrition. 2001;17: 391–6.
2. Cosconati S, Forli S, Perryman AL, Harris R, Goodsell DS, Olson AJ. Virtual screening with AutoDock: theory and practice. Expert Opin Drug Discov. 2010; 5:597-607.
3. Dixi PK, Mittal S. Anti-inflammatory agents of herbal origin: an overview. Int J Res Pharm Sci. 2013;4: 2.
4. Ficarra R, Ficarra P, Tommasini S, Calabrò ML, Ragusa S, Barbera R, et al. A leaf extracts of some Cordia species: analgesic and anti-inflammatory activities as well as their chromatographic analysis. Farm Soc Chim Ital.1995;50:245-56.
5. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001; 345:433-42.
6. Garg V, Dhar VJ, Sharma A, Dutt R. Facts about standardization of herbal medicine: a review. Zhong Xi Yi Jie He Xue Bao. 2012;10:1077-83.
7. Geysen HM, Schoenen F, Wagner D, Wagner R. Combinatorial compound libraries for drug discovery: an ongoing challenge. Nat Rev Drug Discov. 2003;2: 222-30.
8. Gilbert NC, Bartlett SG, Waight MT, Neau DB, Boeglin WE, Brash AR, et al. The structure of human 5-lipoxygenase. Science. 2011;331:217-9.
9. Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by Celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 2000; 60:2101–3.
10. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura Sh, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adelincarcinomas. Cancer Res. 1998;58;1761-4.
11. Julémont F, Dogné JM, Pirotte B, de Leval X. Recent development in the field of dual COX /5-LOX inhibitors. Mini Rev Med Chem. 2004;4:633-8.
12. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46:3-26.
13. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203): 436-44.
14. Martel-Pelletier J, Lajeunesse D, Reboul P, Pelletier JP. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 2003;62:501–9.
15. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. Autodock4 and Auto- DockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30:2785-91.
16. Nariya PB, Bhalodia NR, Shukla VJ, Acharya RN. Antimicrobial and antifungal activities of Cordia dichotoma (Forester F.) bark extracts. Ayu. 2011;32: 585-9.
17. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in ApcD716 knockout mice by inhibition of Cyclooxygenase 2 (COX-2). Cell. 1996;87:803–9.
18. Parisotto EB, Michielin EMZ, Biscaro F, Ferreira SRS, Filho DW, Pedrosa RC. The antitumor activity of extracts from Cordia verbenacea DC obtained by supercritical fluid extraction. J Supercritical Fluids. 2012;61:101-7.
19. Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum. 2001;44:1237–47.
20. Ranjbar MM, Varzi HN, Sabbagh A, Bolooki A, Sazmand A. Study on analgesic and anti-inflammatory properties of Cordia myxa fruit hydroalcoholic extract. Pak J Biol Sci. 2013;16:2066-9.
21. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai Sh, Asai K, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995;55:3785-9.
22. Shahapurkar AA, Jayanthi. Drug neomycin release from Cordia dichotoma transdermal film and anti-inflammatory activity. Int Res J Pharm. 2011;2:107-9.
23. Wang JL, Limburg D, Graneto MJ, Springer J, Hamper JR, Liao S, et al. The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: the second clinical candidate having a shorter and favourable human half-life. Bioorg Med Chem Lett. 2010;20: 7159-63.
24. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 1999;18:7908-16.
25. Ye YN, Wu WK, Shin VY, Bruce IC, Wong BC, Cho CH. Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis. 2005;26:827-34.